Speedy EU review for Shire’s lanadelumab

28th February 2018 Uncategorised 0

European regulators will undertake an accelerated assessment of Shire’s hereditary angioedema (HAE) drug lanadelumab.

More: Speedy EU review for Shire’s lanadelumab
Source: News